| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49ce4737fe7d7213469d90c364f35e29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43fafd54dbde076a99a49571f4658b3e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-08 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-00 |
| filingDate |
1998-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_880fc9458a66d395583b75c3c2561054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e203f8f74cb51b7e8be198f00384fbc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0993d4fa5506593d0e3499acee02b8a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97563f0444de8cc7ce3c05c1466579e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e514beb6f820504587097ec9d5a38f9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de861ac542ff37f633a4c00b4760fde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb5018832d998851a65556b57861eb69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_421848aa921206d9d20e57f256d6a8c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d3ba114377beb76955e855a2ce2360a |
| publicationDate |
2001-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-100273743-B1 |
| titleOfInvention |
Macrolactin F of Streptomyces sp. YB-401 Culture Extract Extract with Inhibitory Effect on Cholesterol Biosynthesis |
| abstract |
The present invention relates to macrolactin F extracted from a microbial culture medium that exhibits an inhibitory effect on cholesterol biosynthesis. More specifically, the present invention relates to macrolactin F, a microbial culture extract preparation that inhibits the activity of squalene synthase, a rate controlling step in the in vivo cholesterol biosynthesis process. Since macrolactin F has activity that inhibits squalene synthase in a concentration-dependent manner, inhibition of macrolactin epro cholesterol biosynthesis promotes the synthesis of low-density low-protein-cholesterol receptors in cells, resulting in blood The level of cholesterol in the body is lowered. In addition, macrolactin F may be used as a prophylactic and therapeutic agent for cardiovascular diseases such as atherosclerosis and coronary artery disease when it is developed as a drug in clinical trials. |
| priorityDate |
1998-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |